China’s First “NGS BRCA Calibration Plan” Was Released! Annoroad Passed the BRCA Genetic Test Industry Evaluation with High Mark
2019.08.02

The results of China’s first NGS BRCA Calibration Plan have been announced, attracting more than 60 participants in this industry. Annoroad, as a representative enterprise with both technology and strength in gene test industry, also participated in this project evaluation, and achieved excellent results in embryonal system BRCA test, tumor tissue BRCA test, and variation interpretation test evaluation. The project completed the first large-scale investigation, variation interpretation and standard product testing of China’s first BRCA test status. Through the active organization and participation of all parties, this will provide an important basis for regulating China’s NGS BRCA test process, improving test quality, correctly interpreting and providing clinically correct reports and clinical treatment.


1.jpg


The “NGS BRCA Calibration Plan” project is hosted by the CAMDI (China Association for Medical Device Industry). The project completed the large-scale investigation, variation interpretation and standard product testing of China’s first BRCA test status, and comprehensively understood the actual situation of domestic BRCA test. Among them, 41 test companies participated in the variation interpretation test, 28 test companies participated in the embryonal system BRCA test ability test, and 20 participated in the tumor tissue BRCA test ability test. The project has profound impact on the establishment of standards and regulations for BRCA test in China. By jointly promoting the BRCA test project specification, it will contribute to the early access to treatment opportunities for cancer patients carrying BRCA mutations.


Annoroad, as a representative enterprise with both technology and strength in gene test industry, also participated in this project evaluation, and passed the variation interpretation ability test with full mark and passed the BRCA standard test with high mark. This shows that Annoroad has superior technical strength in gene mutation test, clinical genetic interpretation analysis, and clinical report normative.


2.jpg


Annoroad has been exploring and researching in breast cancer genetic test field for many years. As early as 2015, Annoroad and the Third Military Medical University Southwest Hospital and other clinical institutions jointly carried out high-risk population screening for breast cancer, and received high attention from experts and scholars at home and abroad. The samples in this research are the only large fragment rearrangement positive samples in the “BRCA Gene Mutant National Reference” and have been successfully included in the national standard and reference list of in vitro diagnostic reagents. The research summary of the subject was included in the 15th St. Gallen International Breast Cancer Conference. In May 2018, the latest research results were published in the international authoritative journal International Journal of Cancer (IF=6.513), it was the largest multi-center, large-sample breast cancer multi-gene screening subject regarding the high risk group for breast cancer in the Asia-Pacific region at that time. This series of achievements reflects the national and international breast cancer diagnosis and treatment community’s high recognition of the project and its research results, as well as the innovation of the project. As the only technical provider of this subject, it demonstrates Annoroad’s powerful genetic test technology. In the future, Annoroad will adhere to the philosophy of “improving the quality of life with science and innovation”, and devote itself to research, develop and innovate precision diagnosis and treatment technology. Annoroad will continue to contribute to the advancement of China’s tumor genomics technology.


Breast Cancer Gene Test

BRCA Gene Mutation and Risk of Breast Cancer

The BRCA1 and BRCA2 genes encode tumor arrest in, which are involved in the replication and repair of double-stranded DNA. Healthy people with brca1/2 mutations has a lifetime risk of breast cancer is 65% and 45%, respectively, and there is a very high risk of breast cancer recurrence after treatment.


One-stop Solution for Breast Cancer Gene Test

Based on high-throughput sequencing technology, Annoroad has carefully selected 230 genes that related to tumor medicine closely, including all genes recommended by the guidelines and clinical hot genes, and analyzed the relationship between more than 266 medicine and gene variations, which can be applied to breast cancer patients, especially in advanced patients with recurrence and metastasis. At the same time, according to the different needs of breast cancer patients in the diagnosis and treatment process, develop a personalized gene Panel and interpret the corresponding medicine.

分享:

Copyright © Annoroad Gene Technology 京ICP备12029022号-1